Education. Evidence. Regrowth.
Prioritize knowledge. Make better choices.
Sort good studies from the bad.
Get bigger hair gains.
PhD's, resarchers, & consumer advocates.
Founder, researcher, & consumer advocate
Our team of PhD’s, researchers, & more
Discover how we conduct our research.
Have questions? Contact us.
Our library of before-after photos.
I have attached my before and afters of my progress since joining this group...
I’m convinced I’ve recovered to probably the hairline I had 3 years ago. Super stoked…
My friends actually told me, “Your hairline improved. Your hair looks thicker...
I also feel my hair has a different texture to it now…
Firstly thank you for your work in this field. I am immensely grateful that...
I just wanted to thank you for all your research, for introducing me to this method...
To be honest I am having fun with all this and I still don’t know how much...
I see a massive amount of regrowth that is all less than about 8 cm long...
150+ member experiences.
Popular treatments. But do they work?
Top-selling ingredients, quantified.
The truth about hair loss "best sellers".
Xyon Health
Strut Health
Happy Head
DS Laboratories
Advanced Trichology
Fully Vital
Xyon Health
DrFormulas
Revivogen MD
Standardized rubrics to evaluate all treatments.
Is this treatment well studied?
How much regrowth can you expect?
Is this treatment safe & sustainable?
Apps, tools, guides, freebies, & more.
100+ free articles.
Our team’s peer-reviewed studies.
Education. Evidence. Regrowth.
PhD's, resarchers, & consumer advocates.
Discover how we conduct our research.
Have questions? Contact us.
Our library of before-after photos.
Read the experiences of members
Finasteride is a drug that lowers dihydrotestosterone (DHT) – a hormone causally linked to androgenic alopecia. Oral finasteride is FDA-approved treatment for androgenic alopecia. It is available in oral, topical, and mesotherapy formulations.
Finasteride lowers DHT by inhibiting an enzyme called type II 5-alpha reductase. At daily doses of 0.2 to 5.0 mg, finasteride can lower DHT by as much as 70%.
Oral finasteride is FDA-approved and is currently the best-studied drug for treating androgenic alopecia. While oral finasteride does come with a risk of sexual side effects, these risks can be mitigated and (sometimes) eliminated by trying lower doses and/or topical formulations.
Finasteride is a drug that lowers dihydrotestosterone (DHT) – a hormone causally linked to androgenic alopecia. Oral finasteride is FDA-approved treatment for androgenic alopecia. It is available in oral, topical, and mesotherapy formulations.
Finasteride lowers DHT by inhibiting an enzyme called type II 5-alpha reductase. At daily doses of 0.2 to 5.0 mg, finasteride can lower DHT by as much as 70%.
Oral finasteride is FDA-approved and is currently the best-studied drug for treating androgenic alopecia. While oral finasteride does come with a risk of sexual side effects, these risks can be mitigated and (sometimes) eliminated by trying lower doses and/or topical formulations.
Finasteride is a drug that lowers dihydrotestosterone (DHT) – a hormone causally linked to androgenic alopecia. Oral finasteride is FDA-approved treatment for androgenic alopecia. It is available in oral, topical, and mesotherapy formulations.
Finasteride lowers DHT by inhibiting an enzyme called type II 5-alpha reductase. At daily doses of 0.2 to 5.0 mg, finasteride can lower DHT by as much as 70%.
Oral finasteride is FDA-approved and is currently the best-studied drug for treating androgenic alopecia. While oral finasteride does come with a risk of sexual side effects, these risks can be mitigated and (sometimes) eliminated by trying lower doses and/or topical formulations.
Explore the science behind hair loss and hair growth. Our in-depth articles cover topics ranging from natural remedies to pharmaceuticals to breakthroughs in hair loss science. Want to request an article topic? Contact us.
Explore the science behind hair loss and hair growth. Our in-depth articles cover topics ranging from natural remedies to pharmaceuticals to breakthroughs in hair loss science. Want to request an article topic? Contact us.
Explore the science behind hair loss and hair growth. Our in-depth articles cover topics ranging from natural remedies to pharmaceuticals to breakthroughs in hair loss science. Want to request an article topic? Contact us.
Want the latest research on Oral Finasteride? Every quarter, our research team conducts a literature search on Oral Finasteride to keep you up-to-date on new studies. See our search criteria & research tables below – including a summary of key findings from every single study.
Last updated: October 2024
Parameter | Inclusion Criteria | Exclusion Criteria |
---|---|---|
Patients | Patients of any age with hair loss. | Patients with no hair loss disorder. |
Intervention | Oral finasteride as a standalone or adjunct therapy. | A study that doesn’t contain oral finasteride either as a standalone or adjunct therapy |
Comparator | Placebo and/or other therapies or baseline. | No comparator. |
Outcomes | Primary Endpoints of phototrichogram, investigator, and/or patient assessments. | Any study not designed to adequately test for the standalone or additive effect of oral finasteride. |
Study Design | Prospective, randomized controlled trials | Literature reviews, non-human subjects, or ongoing clinical trials. |
Study | Participants | Design | Treatment | Results | Key Takeaway | Adverse Effects | Eq | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Authors(year) | Sex | Hair Loss Type | Design | Dose | Usage | Duration | Endpoints | Hair Growth Assessments | Summary | Limitations | Adverse Effects | Jadad Score |
Inadomi (2014) | n=37 Group 1: Hairy in areas other than the head Group 2: Not hairy in areas other than the head. | AGA | Pilot study | Finasteride 1 mg | Once daily | 18.2 months | Patient self-assessment | Group 1: Finasteride was effective (excellent or good) in 88.9% of patients. Group 2: Finasteride was effective (excellent or good) in 31.6% of patients. | Patients who are hairy in areas other than the head appear to respond better to finasteride. | Small sample size, no objective observations. | None reported | 0 |
Oliveira-Soares et al (2013) | n=40 (F) | Normoandrogenic postmenapausal women | Prospective trial | Finasteride 5 mg | Once daily | 18 months | Patient satisfaction, GPA by two assessors with mean taken. | Level of Improvement: Major: 21 Moderate: 15 None: 4 | Daily 5 mg finasteride treatment appears to be an effective and safe treatment for female AGA in postmenapuasal women. | Small sample size, no objective observations. | Libido reduction = 4 Increase in liver enzymes = 1 | 1 |
Yeon (2011) | n=87 (F) | FPHL | Open-label clinical trial | Finasteride 5 mg | Once daily | 12 months | Phototrichogram (hair density and thickness), and GPA using a 7-point scale: greatly decreased ()3), moderately decreased()2), slightly decreased ()1), no change (0), slightly increased(+1), moderately increased (+2), greatly increase (+3) | Hair Density: 90 hairs/cm2 at baseline to 107 hairs/cm2 Hair Thickness: 64 μm at baseline to 70 μm. GPA: 57 patients were rated as ‘slightly increased’, 10 patients were rated as ‘moderately increased’ and 4 patients were rated as ‘greatly increased’. | Oral finasteride at 5 mg/day may be an effective and safe treatment for normoandrogenic women with FPHL. | No randomization or controlling (placebo or other comparator etc). | Headache = 1 (led to withdrawal). Headache, menstrual irregularity, dizziness, and increased body hair = 4 | 1 |
Iorizzo et al (2006) | n=37 (F) | FPHL | Prospective | Finasteride 2.5 mg + Oral contraceptive containing drospirenone 3 mg and ethinyl estradiol 30 μg | Once daily | 12 months | Hair density, GPA, and patient self-assessment. | Hair Density: Mean density of 4.5 at baseline increased to 4.8 at 12 months. GPA: After 12 months, 62% of patients showed improvement in hair loss (32% slightly improved, 22% moderately improved, and 8% greatly improved). Patient Self-Assessment: 29 patients judged their condition as improved, and 8 as stabilized. | 62% of patients demonstrated some improvement to their hair loss after using oral finasteride while taking the oral contraceptive. However, it is unclear whether the results are due to the finasteride or the contraceptive, which has an anti-androgenic effect. | Small sample size, lack of randomization/blinding, and no placebo/comparator. | No adverse effects were reported. | 0 |
Trueb (2004) | n=5 (F) | Postmenopausal women with FPHL | Case-series | Finasteride 2.5 mg (4 patient) or 5 mg (1 patient). | Once daily | Up to 19 months | GPA, and Patient self-assessment | Patient 1: Great improvement stated via GPA Patient 2: Great improvement stated via GPA Patient 3: Slight improvement or no change stated via GPA. Patient 4: Moderate or slight improvement stated via GPA. Patient 5: Slight improvement or no change stated via GPA. All patients reported a slowing down of hair loss around 6 months after treatment, which continued until 12 months. | Oral finasteride in a dosage of 2.5 mg/day or more may be effective for the treatment of pattern hair loss in postmenopausal women. | Case-series rather than a randomized controlled trial. Small sample size and no comparator. | None reported. | 0 |
Arca et al (2004) | n= 65 (M) Group 1: 40 Group 2: 25 | AGA | Open, randomized, comparative study. | Group 1: 1 mg oral finasteride. Group 2: 5% MXT | Group 1: Once daily Group 2: Twice daily | 12 months. | GPA | Group 1: 15% of patients saw dense hair growth, 30% saw moderate growth, 35% saw minimal growth, 18% saw no change, and 3% saw minimal loss. Group 2: 16% of patients saw moderate growth, 36% saw minimal growth, 20% saw no change, 16% saw minimal loss, 8% saw moderate loss, and 4% saw dense loss. | While both treatments appeared effective and safe, oral finasteride treatment was more effective at treating AGA in men than MXT. | No placebo, lack of objective data collection. | Group 1: Loss of libido = 6 Increase in body hair = 1 Group 2: Scalp irritation = 1 | 2 |
Kaufman et al (1998) | n=1553 (M) Group 1: 779 Group 2: 774 | MPHL | Double-blind, placebo-controlled, randomized extension study. | Group 1: 1 mg oral finasteride Group 2: Placebo | Once daily | 12 months. | Hair growth questionnaires& investigator assessments, GPA. | Increase in Hairs: Group 1: 11% increase in hairs. Group 2: 2.7% decrease in hairs. Patient self-assessment: Finasteride was deemed superior to the placebo as early as month 3 into the study. Investigator Assessment: Group 1: 65% of finasteride-treated patients were rated as improved by month 12. Group 2: 37% of placebo-treated patients were rated as improved by month 12. GPA: Group 1: 48% of patients marked as improved by month 12. Group 2: 7% of patients marked as improved by month 12. Serum DHT: Group 1: DHT reduced from 44.0 ng/dl at baseline to 14 ng/dl at month 12. Testosterone increased from 510 ng/dl to 559 ng/dl at month 12. | In a clinical trial that spanned 2 years total, 1 mg daily of oral finasteride slowed the progression of hair loss and increased hair growth. | None reported. | Group 1: Decreased libido - 1.9% Erectile dysfunction - 1.4% Decreased ejaculate volume - 1% Increase in body hair - 0.9% Group 2: Decreased libido - 1.3% Erectile dysfunction - 0.9% Decreased ejaculate volume - 0.4% Increase in body hair - 0.9% | 4 |
Kaufman et al (1998) - Extension of the above study. | n=1215 (M) | MPHL | Double-blind, placebo-controlled, randomized extension study. | Group 1: 1 mg oral finasteride Group 2: Placebo Group 3: Finasteride - placebo Group 4: Placebo - finasteride. | Once daily | 12 months. | Hair growth questionnaires& investigator assessments, GPA. | Increase in Hairs: Groups 1 and 2: The combined analysis demonstrates a difference of 107 hairs between groups by month 12. At month 24, Group 1 maintained the hair counts whilst | In a clinical trial that spanned 2 years total, 1 mg daily of oral finasteride slowed the progression of hair loss and increased hair growth. | None reported. | Group 1: Decreased libido - 1.1%, Erectile dysfunction - 0.7%, Decreased ejaculate volume - 0.2%, Increase in body hair - 0.2%. Group 2: Decreased libido - 1.7%, Increase in body hair - 3%, Urinary frequency - 1.7%, Group 3: Decreased libido - 1.3%, Erectile dysfunction - 1.1%, Increase in body hair - 0.7%. Group 4: No adverse effects reported. | 4 |
Want the latest research on Topical Finasteride? Every quarter, our research team conducts a literature search on Topical Finasteride to keep you up-to-date on new studies. See our search criteria & research tables below – including a summary of key findings from every single study.
Last updated: October 2024
Parameter | Inclusion Criteria | Exclusion Criteria |
---|---|---|
Patients | Patients of any age with hair loss | Patients with no hair loss disorder. |
Intervention | Topical finasteride as a standalone or adjunct therapy. | A study that doesn’t contain topical finasteride either as a standalone or adjunct therapy. |
Comparator | Placebo and/or other therapies or baseline | No comparator. |
Outcomes | Primary Endpoints of phototrichogram, investigator, and/or patient assessments. | Any study not designed to adequately test for the standalone or additive effect of topical finasteride. |
Study Design | Prospective, observational, retrospective, and case series studies. | Literature reviews, non-human subjects, or ongoing clinical trials. |
Study | Participants | Design | Treatment | Results | Key Takeaway | Adverse Effects | Eq | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Authors(year) | Sex | Hair Loss Type | Design | Dose | Usage | Duration | Endpoints | Hair Growth Assessments | Summary | Limitations | Adverse Effects | Jadad Score |
Piraccini et al. (2022) | n = 458 (M) Group 1: 189 Group 2: 184 Group 3: 85 | AGA | Placebo-controlled, double blind, randomized, prospective phase 3 study | Group 1: 0.25% w/w finasteride. Group 2: Topical placebo (same base as finasteride). Group 3: Oral finasteride (1 mg). | 1-4 sprays of 50 µL once daily | 24 weeks | Photo-trichoscopy, GPA using a 7-point scale, patient self-assessment (male hair growth questionnaire). | Hair Count: Group 1: Increase in 20.2 hairs Group 2: 6.7 Group 3: 20.1 Hair Width: No change between treatments. Patient self-assessment – No difference between treatments. Change in Serum DHT: Group 1: 34.5% reduction compared to baseline Group 2: 2.25% increase. Group 3: 55.6% reduction. | Topical finasteride exhibited similar efficacy to oral finasteride for treating AGA, with a reduced change in serum DHT over the course of the study. | Short-follow up. | Patient discontinuation reasons – similar across all treatment groups (323 completed the study). 446 patients contributed safety data. 34% of discontinuations were mild, 18.4% moderate, and 2% severe. 2.8% of topical finasteride treated patients showed some sexual side effects without discontinuation. | 5 |
Suchonwanit et al (2019) | n = 30 (F) Group 1: 15 Group 2: 15. | FPHL | Comparative, randomized, double-blind, prospective study. | Group 1: 0.25% finasteride + 3% minoxidil (FMX). Group 2: 3% minoxidil (MXT). | 1 mL applied twice daily. | 24 weeks | Photo-trichoscopy, GPA using a 7-point rating scale, serum DHT. | Hair Count: Increased with both treatments, but no statistical difference between the two groups (p = 0.88). Hair Diameter: FMX -significantly increased compared to the MXT group (p = 0.02). Serum DHT: FMX group = 33% reduction in DHT (p = 0.016). MXT group = 11% increase. | Combination finasteride and minoxidil exhibited higher efficacy than minoxidil alone. | Small sample size, and short follow-up. | Pruritis (n = 4, FMX); Irritation (n = 1, MXT). | 4 |
Suchonwanit et al. (2018) | n = 40 (M) Group 1: 20 Group 2: 20 | AGA | Comparative, double-blind, randomized prospective study. | Group 1: 0.25% finasteride + 3% minoxidil (FMX). Group 2: 3% minoxidil (MXT). | 1 mL applied twice daily. | 24 weeks | Photo-trichoscopy, GPA using a 7-point rating scale, Serum DHT, patient self–assessment. | Hairs per cm2: Group 1: 61.84 ± 15.65, Group 2: 34.88 ± 10.24 (p = 0.05). Hair diameter: Group 1: 17 ± 5.24µm, Group 2: 13 ± 4.15µm (p = 0.05). GPA: FMX performed better than MXT (p = 0.026) with 63.1% as marked improvement. Patient self-assessment: 52.6% showed marked improvement with FMX. Serum DHT: Group 1: 5.7% reduction in DHT Group 2: 7.4% reduction (p = 0.92). | Treatment with FMX was significantly superior to MXT alone for promoting hair growth in AGA. | No long-term follow-up and no evaluation of scalp DHT. | No serious adverse events or sexual problems reported. Headache (n = 1 MXT); Dry flaky scalp (n = 3 FMX, n = 2 MXT). Pruritis (n = 2) | 4 |
Tanglertsampan, C. (2012) | n = 40 (M) Group 1: 20 Group 2: 20 | AGA | Comparative, double-blind, randomized, prospective study. | Group 1: 0.1% topical finasteride (1 mg dose), combined with 3% minoxidil (FMX). Group 2: 3% minoxidil (MXT). | 1 mL applied twice daily | 24 weeks | Video dermoscopy for hair density. GPA using a 7-point rating scale | Hair Count: No statistical difference in hair count between FMX group compared to the MXT group alone by week 24 (p = 0.503). GPA: Group 1: 1.84 ± 0.79 Group 2: 1.02 ± 0.69 | GPA assessment show significantly greater improvement in the FMX group compared to MXT alone. | Small sample size, and short follow-up. | Contact dermatitis (n = 4 of 17, FMX; n = 6 of 16, MXT). No significant difference. No sexual adverse effects. | 4 |
Hajheydari et al. (2009). | n = 45 (M) Seven were excluded Group 1: 19 Group 2: 19 | AGA | Comparative, double-blind, randomized, prospective study. | Group 1: 1% finasteride gel + placebo. Group 2: 1 mg finasteride + placebo gel. | Gel applied twice daily + 1 tablet (placebo or finasteride) taken once daily. | 24 weeks | Patient self-assessment, expert grading of bald spots, terminal hair count, and vellus hair. | No statistical difference between oral and topical finasteride. | Therapeutic effects of both finasteride gel and tablets were relatively similar to each other. | Small sample size, and short, follow-up. | Finasteride gel- Erythema (n = 1) Finasteride oral - decreased libido (n = 1) | 4 |
Mazzarella et al. (1997) | n = 52 28 (M) 24 (F) Group 1: 26 and Group 2: 26. | AGA | Placebo-controlled, single-blind, non-randomized, prospective study. | Group 1: 0.005% finasteride. Group 2: Placebo. | 1mL applied twice daily. | 64 weeks | Hair wash test and GPA using a 5-point scale, patient self–assessment using a 4-point scale. | GPA: No significant regrowth for the first 3 months (scores between 1-2). Group 1: score of 4 (n = 12) and 3 (n = 14). Group 2: high rate of dropout (n = 10) due to lack of response – score of 2 (n = 3), score of 1 (n = 3), score of 0 (n = 4). Wash Test: After 16 months - Group 1: count = 36.8 ± 8.1, Group 2 = 54.2 ± 6.2. (p = <0.0001). Self-assessment: Group 1:- 73% scored a 3, 27% scored a 2. Group 2: 2 in one patient, 1 in three patients, and 0 in six patients. | The clinical outcome in terms of both hair growth and balding area reduction appeared encouraging - especially with no systemic effects observed. | Small sample size. | No adverse effects reported. | 2 |
Want the latest research on Mesotherapy Finasteride? Every quarter, our research team conducts a literature search on Mesotherapy Finasteride to keep you up-to-date on new studies. See our search criteria & research tables below – including a summary of key findings from every single study.
Last updated: October 2024
Parameter | Inclusion Criteria | Exclusion Criteria |
---|---|---|
Patients | Patients of any age with hair loss. | Patients with no hair loss disorder. |
Intervention | Mesotherapy finasteride as a standalone or adjunct therapy. | A study that doesn’t contain mesotherapy finasteride either as a standalone or adjunct therapy. |
Comparator | Placebo and/or other therapies or baseline. | No comparator. |
Outcomes | Primary Endpoints of phototrichogram, investigator, and/or patient assessments. | Any study not designed to adequately test for the standalone or additive effect of mesotherapy finasteride. |
Study Design | Prospective, observational, retrospective, and case series studies. | Literature reviews, non-human subjects, or ongoing clinical trials. |
Study | Participants | Design | Treatment | Results | Key Takeaway | Adverse Effects | Eq | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Authors(year) | Sex | Hair Loss Type | Design | Treatment Types | Treatment Regimen | Procedure | No. of Sessions | Duration | Endpoints | Hair Growth Assessments | Summary | Limitations | Adverse Effects | Jadad Score |
Talwar(2017) | n=40 Group 1: 20 Group 2: 20 | AGA | Comparative trial. | Mesotherapy finasteride and oral finasteride (1 mg). | Group 1: Mesotherapy finasteride Group 2: Oral finasteride (1 mg). | Group 1: Topical finasteride injected with a mesotherapy needle using nappage technique. Group 2: 1 mg oral finasteride daily. | 6 (Once every 2 weeks) | 12 weeks + 6 months follow-up at after the last dose. | GPA, patient satisfaction, hair pull tests. | GPA: Group 1: After 6 sessions 70% of participants were in the excellent improvement category for hair growth. Group 2: After six sessions 60% of participants were in the excellent improvement category. Patient self-assessment: Group 1: Marked improvement = 60% Group 2: Marked improvement = 60%. | Mesotherapy with topical finasteride showed promise in the treatment of AGA in men. | Small sample size. | Group 1: Loss of libido (5%), folliculitis (2%). Group 2: Loss of libido (10%), erectile dysfunction (5%). | 1 |